What is Neuron23?
Neuron23 is a biotechnology enterprise dedicated to the development of precision medicines for genetically defined neurological and immunological diseases. By integrating state-of-the-art AI-enabled drug discovery with sophisticated biomarker platforms, the company identifies and validates therapeutic targets with high precision. Its core focus spans neurodegenerative, neuroinflammatory, and systemic autoimmune disorders, positioning the firm at the intersection of computational biology and clinical pharmacology. The company's market position is bolstered by a robust intellectual property portfolio and a strategic focus on translating genetic insights into actionable, life-changing treatments.
How much funding has Neuron23 raised?
Neuron23 has raised a total of $310M across 4 funding rounds:
Series B
$80M
Series A
$33.5M
Series C
$100M
Series D
$96.5M
Series B (2020): $80M with participation from Acorn Bioventures, Redmile Group, Westlake Village BioPartners, Perceptive Advisors, Cowen Healthcare Investments, HBM Partners, Kleiner Perkins, and Surveyor Capital (a Citadel company)
Series A (2020): $33.5M led by Kleiner Perkins and Westlake Village BioPartners
Series C (2022): $100M supported by Kleiner Perkins, Surveyor Capital, SoftBank Group Corp, Redmile Group, Westlake Village BioPartners, Cowen Healthcare Investments, Perceptive Advisors, Acorn Bioventures, and HBM Partners
Series D (2025): $96.5M featuring Acorn Bioventures, Westlake Village BioPartners, HBM Healthcare Investments, Redmile Group, Softbank Vision Fund, Kleiner Perkins, and Blue Owl
Key Investors in Neuron23
Kleiner Perkins
A Menlo Park-based venture capital firm that invests in early and growth-stage technology and life science companies, providing operational support from seed through IPO.
Westlake Village BioPartners
A life science venture capital firm focused on incubating and investing in world-class entrepreneurs to create innovative biotech companies that address significant unmet patient needs.
Acorn Bioventures
An investment firm specializing in small-cap public and private biotechnology companies, providing flexible capital solutions across the entire spectrum of drug development.
What's next for Neuron23?
With the successful closure of this major strategic investment, Neuron23 is well-positioned to scale its operational capabilities and advance its lead candidates through critical clinical milestones. The company is expected to prioritize the expansion of its AI-driven discovery engine, further refining its ability to predict therapeutic efficacy in genetically stratified patient cohorts. As the firm matures, the focus will likely shift toward establishing strategic partnerships and preparing for potential commercialization pathways, ensuring that its innovative pipeline reaches patients suffering from devastating diseases. The continued support from top-tier life science investors provides the stability required to navigate the complex regulatory and development landscapes inherent in the biotech sector.
See full Neuron23 company page
